請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34307
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳保中(Pau-Chung Chen) | |
dc.contributor.author | Hsing-Hua Lin | en |
dc.contributor.author | 林杏樺 | zh_TW |
dc.date.accessioned | 2021-06-13T06:02:22Z | - |
dc.date.available | 2015-10-03 | |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-26 | |
dc.identifier.citation | Reference <1>
Arlt VM, Stiborova M, Schmeiser HH. 2002. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17(4): 265–277. Arlt VM, Alunni-Perret V, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels JF, Meyrier A, Cassuto E, Wiessler M, Schmeiser HH, Cosyns JP. 2004. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 111(6): 977–980. CCMP. Committee on Chinese Medicine and Pharmacy, Department of Health. 2003. [in Chinese] Available from: http://www.ccmp.gov.tw/public/public.asp?selno=816&relno=816&level=C. Chang CH, Wang YM, Yang AH, Chiang SS. 2001. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 21(6): 441–448. Cosyns JP, Jadoul M, Squifflet JP, Van Cangh PJ, van Ypersele de Strihou C. 1994. Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 344(8916): 188. Cosyns JP, 2003. Aristolochic acid and Chinese herbs nephropathy: a review of the evidence to date. Drug Saf 26(1): 33–48. Cronin AJ, Maidment G, Cook T, Kite GC, Simmonds MS, Pusey CD, Lord GM. 2002. Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 17(3): 524–525. Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem JL. 1994. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24(2): 172-180. FDA. 2000. Letter to health care professionals - FDA concerned about botanical products, including dietary supplements, containing aristolochic acid. U.S. Food and Drug Administration. Available from: http://vm.cfsan.fda.gov/~dms/ds-botl2.html. FDA. 2001a. Listing of Botanical Ingredients of Concern. U.S. Food and Drug Administration. Available from: http://www.fda.gov/Food/DietarySupplements/Alerts/ucm095283.htm. FDA. 2001b. Aristolochic Acid: FDA Warns Consumers to Discontinue Use of Botanical Products that Contain Aristolochic Acid. U.S. Food and Drug Administration. Available from: http://www.fda.gov/Food/DietarySupplements/Alerts/ucm096388.htm. FDA. 2001c. Letter to industry associations regarding safety concerns related to the use of botanical products containing aristolochic acid. U.S. Food and Drug Administration. Available from: http://www.cfsan.fda.gov/~dms/ds-botl4.html. Gillerot G, Jadoul M, Arlt VM, van Ypersele De Strihou C, Schmeiser HH, But PPH, Bieler CA, Cosyns JP. 2001. Aristolochic acid nephropathy in a Chinese patient: time to abandon the term 'Chinese herbs nephropathy'? Am J Kidney Dis 38(5): E26. Hong YT, Fu LS, Chung LH, Hung SC, Huang YT, Chi CS. 2006. Fanconi's syndrome, interstitial fibrosis and renal failure by aristolochic acid in Chinese herbs. Pediatr Nephrol 21(4): 577–579. IARC. 2002. Some Traditional Herbal Medicines, Some Mycotoxins, Napthalene and Styrene, IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. International Agency for Research on Cancer 82: 69–128. Izumotani T, Ishimura E, Tsumura K, Goto K, Nishizawa Y, Morii H. 1993. An adult case of Fanconi syndrome due to a mixture of Chinese crude drugs. Nephron 65(1): 137–140. Jacob SS, Smith NW, Legido-Quigley C. 2007. Assessment of Chinese medicinal herb metabolite profiles by UPLC-MS-based methodology for the detection of aristolochic acids. J Sep Sci 30: 1200–1206. Kumar V, Poonam, Prasad AK, Parmar VS. 2003. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat Prod Rep 20(6): 565–583. Kuo CH, Lee CW, Lin SC, Tsai IL, Lee SS, Tseng YJ, Kang JJ, Peng FC, and Wei-Chu L. 2010. Rapid determination of aristolochic acids I and II in herbal products and biological samples by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta 80(5): 1672–80. Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O, Beauwens R. 2001. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int 60(4): 1332-1342. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL. 2005. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 20(11): 2321-32. Lee S, Lee T, Lee B, Choi H, Yang M, Ihm CG, Kim M. 2004. Fanconi's syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology (Carlton) 9(3): 126–129. Liu Y, Lin A, Wu Z, Ou R, Huang H. 2010. A liquid chromatography/tandem mass spectrometry method for determination of aristolochic acid-I in rat plasma Biomed. Chromatogr. 24: 174–179. Lo SH, Mo KL, Wong KS, Poon SP, Chan CK, Lai CK, Chan A. 2004. Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis. Nephrol Dial Transplant 19(7): 1913–1915. Lo SH, Wong KS, Arlt VM, Phillips DH, Lai CK, Poon WT, Chan CK, Mo KL, Chan KW, Chan A. 2005. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am J Kidney Dis 45(2): 407–410. Lord GM, Tagore R, Cook T, Gower P, Pusey CD. 1999. Nephropathy caused by Chinese herbs in the UK. Lancet 354(9177): 481–482. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. 2001. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358(9292): 1515–1516. Mengs U. 1987. Acute toxicity of aristolochic acid in rodents. Arch Toxicol 59(5): 328-331. Meyer MM, Chen TP, Bennett WM. 2000. Chinese herb nephropathy. Proc (Bayl Univ Med Cent) 13(4): 334–337. NTP. 2008 Report on Carcinogens Background Document for Aristolochic Acids. National Toxicology Program Pena JM, Borras M, Ramos J, Montoliu J. 1996. Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol Dial Transplant 11(7): 1359–60. Sun D, Feng J, Dai C, Sun L, Jin T, Ma J, Wang L. 2006. Role of peritubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy. Am J Nephrol 26(4): 363-71. Tanaka A, Nishida R, Yoshida T, Koshikawa M, Goto M, Kuwahara T. 2001. Outbreak of Chinese herb nephropathy in Japan: are there any differences from Belgium? Intern Med 40(4): 296–300. Tsai CS, Chen YC, Chen HH, Cheng CJ, Lin SH. 2005. An unusual cause of hypokalemic paralysis: aristolochic acid nephropathy with Fanconi syndrome. Am J Med Sci 330(3): 153–5. Ubara Y, Hara S, Kobayashi M, Katori H, Tagami T, Yokota M, Kitamura Y, Yoshihara K, Matsushita Y, Yokoyama K, Takemoto F, Yamada A, Ishida A, Endo Y, Hara M. 1999. A case of Chinese herbs - induced renal interstitial fibrosis associated with fibrosis of salivary glands. Am J Kidney Dis 33(3): 1–5. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. 1994. Identification of aristolochic acid in Chinese herbs. Lancet 343(8890): 174. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. 1993. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341(8842): 387–391. Yang CS, Lin CH, Chang SH, Hsu HC. 2000. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 35(2): 313–318. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou TJ, Liu JH, Chen PM. 2002. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 59(5): 681–7. Yang HY, Lin JL, Chen KH, Yu CC, Hsu PY, Lin CL. 2006. Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol 19(1): 111–114. Yue H, Chan W, Guo L, Cai Z. 2009. Determination of aristolochic acid I in rat urine and plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B 877 : 995–999. Reference <2> ATSDR (Agency for Toxic Substances and Disease Registry). 1999. Public Health Service: Toxicological Profile for Mercury. U.S. Department of Health and Human Services. Bureau of Health Promotion, Department of Health, Taiwan. 2007. Annual report. [in Chinese]. Available from: http://olap.bhp.doh.gov.tw/search/ListHealth1.aspx?menu= 1&mode=8&year= 96&sel=0&mid=3. Last accessed November 10, 2010. CCMP. Committee on Chinese Medicine and Pharmacy, Department of Health. 2003. [in Chinese] Available from: http://www.ccmp.gov.tw/public/public.asp?selno=816&relno=816&level=C. Chu NF, Liou SH, Wu TN, Ko KN, Chang PY. 1998. Risk factors for high blood lead levels among the general population in Taiwan. Eur J Epidemiol 14: 775-781. Chuang MS, Hsu YH, Chang HC, Lin JH, Liao CH. 2002. Studies on adulteration and misusage of marketed Akebiae caulisn [in Chinese]. Ann Rept NLFD Taiwan ROC 20: 104–119. Deng JS. 2002. Quality Evaluation of Fang-Ji and Analysis of Marker Constituents [dissertation] Taichung, Taiwan : Institute of Chinese Pharmaceutical Sciences, China Medical University 75-77. de Burbure C, Buchet JP, Leroyer A, Nisse C, Haguenoer JM, Mutti A, Smerhovsky Z, Cikrt M, Trzcinka-Ochocka M, Razniewska G, Jakubowski M, Bernard A. 2006. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 114: 584-590. Ernst E, Thompson Coon J. 2001. Heavy metals in traditional Chinese medicines: a systematic review. Clin Pharmacol Ther 70: 497-504. Ernst E. 2002. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 23: 136-139. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. 1999. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81: 542-548. Gundacker C, Komarnicki G, Zodl B, Forster C, Schuster E, Wittmann K. 2006. Whole blood mercury and selenium concentrations in a selected Austrian population: does gender matter? Sci Total Environ 372: 76-86. Guh JY, Chen HC, Tsai JF, Chuang LY. 2007. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis 49: 626-633. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, Horng SS, Chang YK, Yang WC. 2006. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 48:727-38. Hsu CS, Liu PL, Chien LC, Chou SY, Han BC. 2006. Mercury concentration and fish consumption in Taiwanese pregnant women. BJOG 114: 81-85. Hsu YH, Tseng HH, Wen KC. 1997. Determination of aristolochic acid in Fangchi radix [in Chinese]. Ann Rept NLFD Taiwan ROC 15: 136-142. Hsu YH, Lo CF, Chang HC, Lin JH. 2003. Studies on adulteration and misusage of Asari radi in the market [in Chinese]. Ann Rept NLFD Taiwan ROC 21:153- 167. IARC (International Agency for Research on Cancer). 1997. Mercury and Mercury Compounds. IARC Monogr Eval Carcinog Risks Hum 58: 239-268. IARC (International Agency for Research on Cancer). 2002. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 82: 69-118. Ikeda M, Zhang ZW, Moon CS, Imai Y, Watanabe T, Shimbo S, Ma WC, Lee CC, Guo YL. 1996. Background exposure of general population to cadmium and lead in Tainan city, Taiwan. Arch Environ Contam Toxicol 30: 121-126. Jong TT , Lee MR , Hsiao SS ,Hsai JL, Wu TS, Chiang ST, Cai SQ. 2003. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/ atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal 33 (4): 831–837. Kabelitz L. 1998. Heavy metals in herbal drugs (Zur Schwermetallbelastung von Arznei- und Krauterdrogen) [in German]. Pharm Ind 60:444-51. Koh HL, Woo SO. 2000. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 23: 351-362. Lai LH, Chou SY, Wu FY, Chen JJ, Kuo HW. 2008. Renal dysfunction and hyperuricemia with low blood lead levels and ethnicity in community-based study. Sci Total Environ 401: 39-43. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. 2009. Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk. J Natl Cancer Inst 102: 1–8. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, and Wang JD. 2010. Risks of Kidney Failure Associated With Consumption of Herbal Products Containing Mu Tong or Fangchi: A Population-Based Case-Control Study. American Journal of Kidney Diseases 55(3): 507-518. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-70. Lynch E, Braithwaite R. 2005. A review of the clinical and toxicological aspects of 'traditional' (herbal) medicines adulterated with heavy metals. Expert Opin Drug Saf 4: 769-778. Maldonado G, Greenland S. 1993. Simulation study of confounder-selection strategies. Am. J. Epidemiol 138: 923–936. NTP (National Toxicology Program). 2008. Report on Carcinogens Background Document for Aristolochic Acids. NIH Publication no. 08-5976. Available from: http://ntp.niehs. nih.gov/ NTP/roc/twelfth/2010/FinalBDs/AristolochicAcids20101014.pdf. Navas-Acien A, Tellez-Plaza M, Guallar E, Muntner P, Silbergeld E, Jaar B, Weaver V. 2009. Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis. Am J Epidemiol 170: 1156-1164. PCCMP (Pharmacopoeia Commission of the Chinese Ministry of Public Health). 1995. Pharmacopoeia of the People's Republic of China. Guangdong Technology Publisher and Chemical Industries Publisher Vol. 1. Thatte UM, Rege NN, Phatak SD, Dahanukar SA. 1993. The flip side of Ayurveda. J Postgrad Med 39: 179-182. USRDS (United States Renal Data System). 2010. The 2010 USRDS Annual Data Report (ADR) Available from: http://www.usrds.org/atlas.htm. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. 1993. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341(8842): 387-391. Wu MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Chen CJ, Lee TC. 2001. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109:1011–17. Yang HY, Wang JD, Lo TC, Chen PC. 2009. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J Epidemiol 19: 17-23. Yang HY, Wang JD, Lo TC, Chen PC. 2010. Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids. Occup Environ Med 10: 1136. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34307 | - |
dc.description.abstract | 中文摘要<一>
研究背景與目的:馬兜鈴酸 (Aristolochic acids, AA) 為腎毒性物質且具突變性及致癌作用。職業醫學研究報告指出中藥從業人員腎臟癌之標準化死亡比(Standardized mortalityratio, SMR) 顯著高於一般民眾。中藥從業人員可能於藥材之收集、製程和配製過程中暴露馬兜鈴酸,且亦可能會服用較多含馬兜鈴酸之藥材。因此,本研究目的為偵測自2003年禁用馬兜鈴酸後,中藥從業人員及其家屬血清中馬兜鈴酸 (AA I /AA II) 之濃度,並評估中藥從業人員馬兜鈴酸之職業暴露情形。 材料與方法:本研究於2007 年5 - 6 月期間,收集共171 位中藥師公會成員(包含38 位家屬)之血液檢體。取250 μL 的血清樣本後,添加25 ng/mL 氟硝西泮-D7 內標準品,以850 μL 乙腈溶液,進行蛋白質沉澱。經由超音波震盪及高速離心,取上清液過濾後,以減壓離心濃縮至近乾,上機前以20 μL 甲醇回溶。定量AA I 與AA II 分析物,則採用Waters 極致液相層析(Acquity UPLC) 結合Waters Quattro Premier XE 三段式四極棒質譜儀 (triple-quadrupole mass spectrometer)。本研究使用BEH C18 管柱 (2.1 × 50 mm, 1.7μm),流速為0.5 μL/min,層析移動相則為10 mM 甲酸銨緩衝溶液 (pH = 3.0) 與乙腈。分析物之游離化方式,則使用電灑游離法(electrospray ionization) 於正離子模式,進行選擇性反應偵測 (selected reaction monitoring, SRM)。 結果:本研究提供人體血清中微量濃度之馬兜鈴酸 (AA I/AA II) 定性兼定量檢測分析方法。分析方法之回收率達到95-112%。 AA I 與AA II 之偵測極限 (定義為 3 倍的訊號/雜訊比) 分別為 0.014 與 0.063 ng/mL。本研究進行人體血清檢體檢測結果顯示,AAI濃度高於偵測極限僅 28 位,AA II 則皆未檢出。於中藥從業人員及其家屬之血清檢體中AAI平均濃度分別為 0.064 ng/mL (n =24) 和0.044 ng/mL (n= 4)。24位偵測到AAI之中藥從業人員中,有20位處理過含馬兜鈴酸藥材,5位曾服用含馬兜鈴酸藥材。 結論:本研究是第一篇評估人體血清中馬兜鈴酸之暴露濃度,針對禁用含馬兜鈴酸藥材四年後所收集之血清檢體,仍有少數約16.4% 檢體偵測到極微量(濃度接近偵測極限)AA I,顯示國內中草藥之安全性仍需建立更嚴謹之把關機制。 中文摘要<二> 材料與方法:本研究於2007 年5-6 月期間,收集共138 位中藥師公會成員之血液檢與問卷。使用感應耦合電漿質譜分析儀分析血中重金屬濃度。採用極致液相層析-串聯質譜儀分析血清中馬兜鈴酸濃度。根據Modification of Diet in Renal Disease Study 的公式計算估計腎絲球過濾速率(eGFR)。若eGFR< 60 (ml/min/1.73m2)為慢性腎衰竭(Chronic kidney diseas)。 結果:共22位(15. 9%)中藥從業人員為慢性腎衰竭。血中重金屬平均濃度分別為砷(5.01 μg/L)、鎘(2.04 μg/L)、汞(19.92 μg/L)、鉛(51.06μg/L)。調整工作年資、性別、身體質量指數、抽菸、喝酒、收縮壓、糖尿病和尿酸後,汞(per log10 unit: β = -11.80,95% CI -22.5 to -1.0) 和鉛(per log10 unit: β= -9.79, 95% CI -16.7 to -2.9) 與eGFR呈負相關,且汞和鉛具顯著交互作用關係(p = 0.01)。中藥從業人員之血清檢體中AAI平均濃度為 0.06 ± 0.02 ng/mL。調整干擾因子及重金屬濃度後,處理馬兜鈴酸藥 材的工作年資(β = -0.01, 95% CI -0.2 to 0.1)與馬兜鈴酸之累積暴露量(β = -0.11,95% CI -2.5 to 2.3)和eGFR呈負相關但未達統計上顯著意義。 結論:相較於馬兜鈴酸禁用後之極低劑量暴露,中藥從業人員暴露至較高濃度之鉛、汞顯著降低其腎功能表現。顯示國內中草藥之安全性仍需建立更嚴謹之重金屬及馬兜鈴酸檢驗把關機制以保護中藥從業人員及一般民眾之健康。 | zh_TW |
dc.description.abstract | Abstract <1>
Background and Objectives: Aristolochic acids (AAs) are known to be strongly nephrotoxic and carcinogenic. Occupational studies showed that the SMR for kidney cancer were significantly higher for the Chinese herbalists. Herbalists are potentially exposed to aristolochic acids while gathering plants, preparing or applying herbal remedies and may also consume more AAs contained herbs. This study was to determine the AAs levels in serum of herbalists and family members to access the exposure of aristolochic acid after the ban of herbs containing AAs in Taiwan. Methods: A total of 171 subjects were members of the Occupational Union of Chinese Herbalists, recruited between May and June 2007 in Taiwan. Serum samples were processed with protein precipitation using acentonitrile mixed with an internal standard,flunitrazepam-D7 and were analyzed by ultra-high-pressure liquid chromatography tandem mass spectrometry. The instrument is operated in selected reaction monitoring (SRM) with an electrospray ionization source in positive ionization mode. The analytes were separated within4 min by a Acquity BEH C18 column (2.1mm×50mm,1.7μm) with 10 mM ammonium formate (pH = 3) / acentonitrile gradient elution at a flow rate of 0.5 mL/min. Results: The method exhibited good linearity over the concentration range of 0.05–100 ng/mL and 0.4–100 ng/mL for AA I and AA II. Intra- and inter-day precisions of calibration were less than 9.3% relative standard deviation. Accuracy was tested by spiking three 4 different concentrations (0.4, 1.0 and 10 ng/mL) in bovine serum and the recoveries ranged from 95 to 112%. The limits of detction (LODs) were 0.014 and 0.063 ng/mL for AAI and AAII respectively, which were sensitive enough for determining AAs levels in human serum. Under optimum UHPLC–MS/MS conditions, a total of 28 subjects’ AAI levels were detected above the LOD (0.014 ng/mL). AAII wasn’t detected in any serum samples. The mean concentration of AAI in herbalists and family members were 0.064 ng/mL(n=24) and 0.044 ng/mL(n=4), respectively. Moreover, 20 herbalists who was detected AAI in serum have ever processed herbs containing aristolochic acids. Conclusions: The present study is, to our knowledge, the first study determining the AAs levels in human serum. AAI was still detected in 28 (16.4%) serum which was collected in 2007, four years after the ban of herbs containing aristolochic acids in Taiwan. Abstract <2> Objective: We examined the association between multiple heavy metals and aristolochic acid levels and the estimated glomerular filtration rate (eGFR) in herbalists. Methods: A total of 138 subjects were members of the Occupational Union of Chinese Herbalists, recruited between May and June 2007 in Taiwan. Heavy metals in blood samples were analyzed by Agilent 7500C inductively coupled plasma-mass spectrometry. Aristolochic acids (AAs) in serum were measured by UHPLC-MS/MS. Renal function was assessed by using a simplified Modification of Diet in Renal Disease Study equation to estimate glomerular filtration rate (eGFR). Subjects with eGFR levels below 60 (ml/min/1.73m2) were regarded as having chronic kidney disease. Results: There were 22 (15.9%) subjects with chronic kidney disease. Heavy metal 44 concentrations of arsenic, cadmium, mercury and lead in blood were 5.01 ± 4.8, 2.04 ± 2.3, 19.92 ± 14.8, and 51.06 ± 54.0 μg/L, respectively. After adjusting for work years gender, body mass index, systolic pressure, diabetes, cigarette smoking, alcohol drinking and uric acid, in multi-metal analysis, there were significant negative effects for eGFR levels in mercury (per log10 unit: β = -11.80, 95% CI -22.5 to -1.0) and lead (per log10 unit: β= -9.79, 95% CI -16.7 to -2.9) with a significant interaction (p = 0.01) between mercury and lead. Aristolochic acid I was detected in 24 (17.4%) herbalists, the mean concentration was 0.06 ± 0.02 ng/mL, and there was negative correlation between eGFR and AAI concentration but without significant (r = -0.40, p=0.07, n=24). Duration of processing AA-herbs (β = -0.01, 95% CI -0.2 to 0.1 and cumulative AA exposure (β = -0.11, 95% CI -2.5 to 2.3) were negatively associated with eGFR after adjusting other confounders and heavy metal levels but without significant effect. Conclusions: We found the independent renal effects of mercury and lead in herbalists after the ban of herbs containing aristolochic acids in Taiwan. Although the AAs exposure did not show a significantly negative effect on eGFR in this study, the rigorous monitoring of toxic heavy metals and aristolochic acids in herbs is still needed to protect not only herbalists but also the general population who take herbs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:02:22Z (GMT). No. of bitstreams: 1 ntu-100-R98841005-1.pdf: 2355381 bytes, checksum: 19bf3b84da85999b40709ef8ac447ccf (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄<一>
中文摘要 1 ABSTRACT 3 FIGURE OF CONTENTS 6 TABLE OF CONTENTS 7 INTRODUCTION 8 MATERIALS AND METHODS 12 CHEMICALS AND REAGENTS 12 SAMPLE COLLECTION AND SAMPLE PREPARATION 12 INSTRUMENTAL ANALYSIS AND QUANTIFICATION 14 EVALUATION OF MATRIX EFFECT AND EXTRACTION EFFICIENCY OF SAMPLE PRETREATMENT 16 METHOD VALIDATION 16 RESULTS AND DISCUSSION 18 METHOD PERFORMANCE, MATRIX EFFECT AND RECOVERY 18 METHOD VALIDATION 19 CONCLUSION 21 REFERENCE 22 APPENDIX. THE METHODS OF MEASURING ARISTOLOCHIC ACIDS IN BIOLOGICAL SAMPLES. 40 目錄<二> 中文摘要 42 ABSTRACT 43 FIGURE OF CONTENTS 46 TABLE OF CONTENTS 47 INTRODUCTION 48 MATERIALS AND METHODS 51 STUDY OF POPULATION AND DATA COLLECTION 51 MEASUREMENTS OF HEAVY METALS 51 MEASUREMENTS OF ARISTOLOCHIC ACIDS 52 RENAL FUNCTION 53 STATISTICAL ANALYSIS 54 RESULTS 56 DISCUSSION 58 CONCLUSIONS 64 REFERENCE 65 | |
dc.language.iso | en | |
dc.title | 一、分析馬兜鈴酸藥材禁用後中藥從業人員及家屬血清中馬兜鈴酸之濃度;二、評估馬兜鈴酸藥材禁用後中藥從業人員血中鉛、汞及馬兜鈴酸與腎功能之相關性 | zh_TW |
dc.title | 1. Aristolochic acids levels in serum of Chinese herbalists and family members after the ban of herbs containing aristolochic acids in Taiwan;2. Renal effects of lead, mercury, and aristolochic acids in herbalists in Taiwan after the ban of herbs containing aristolochic acids in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 薛玉梅(Yu-Mei Hsueh),郭憲文(Hsien-Wen Kuo),郭錦樺(Ching-Hua Kuo),楊孝友(Hsiao-Yu Yang) | |
dc.subject.keyword | 中藥從業人員,馬兜鈴酸,極致液相層析-串聯質譜儀,重金屬,慢性腎衰竭, | zh_TW |
dc.subject.keyword | Herbalists,aristolochic acids,UHPLC-MS/MS,heavy metals,chronic kidney disease, | en |
dc.relation.page | 76 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
顯示於系所單位: | 職業醫學與工業衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.3 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。